Compare Vanguard Global ex-US Real Estate Index Fd ETF (VNQI) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Global ex-US Real Estate Index Fd ETF vs Viatris Inc — how do they compare? Vanguard Global ex-US Real Estate Index Fd ETF trades at $45.51, while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Viatris Inc pays a 2.95% dividend while Vanguard Global ex-US Real Estate Index Fd ETF pays none, and Viatris Inc is trading nearer its 52-week high, Vanguard Global ex-US Real Estate Index Fd ETF nearer its low. Which is the better fit depends on your goals.
| VNQI | VTRS | |
|---|---|---|
52-Week High | $50.76 | $17.86 |
52-Week Low | $43.26 | $9.49 |
Market Cap | — | $18.69B |
Sector | — | Health |
Enterprise Value | — | $30.80B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VNQI (Vanguard Global ex-U.S. Real Estate ETF) trades at $45.77, up 0.46% with a bullish technical signal from moving averages. The ETF provides diversified international real estate exposure across 30+ countries outside the U.S., featuring a low expense ratio and higher dividend yield compared to domestic REIT ETFs. Recent news highlights ongoing comparisons with competing real estate funds, with VNQI's international diversification being a key differentiator.
The outlook for VNQI remains positive given its global real estate diversification benefits and income-oriented profile. Key opportunities include exposure to growing international property markets and attractive dividend yield, while risks involve currency fluctuations, geopolitical uncertainties, and potential underperformance relative to U.S. real estate markets. The ETF's low-cost structure supports long-term total return potential for investors seeking international real estate exposure.
Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.
Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vanguard Global ex-US Real Estate Index Fd ETF
The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
